Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 10/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29791829 | 1.00 | IDO1 (0.44) | IDO1ARCYP2C19CYP1A2CYP3A4 | |
| SCHEMBL24176753 | 0.86 | IDO1 (0.40) | IDO1ARCYP2C19CYP1A2CYP3A4 | |
| SCHEMBL24176681 | 0.83 | AR (0.42) | ARCYP2C19CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24176787 | 0.79 | TRPV4 (0.44) | AR | |
| SCHEMBL28697729 | 0.76 | IDO1 (0.39) | IDO1AR | |
| SCHEMBL24838713 | 0.75 | CYP2A6 (0.45) | CYP2C19CYP1A2CYP3A4CYP2C9CYP2E1 | |
| SCHEMBL30178751 | 0.75 | CYP2A6 (0.45) | CYP2C19CYP1A2CYP3A4CYP2C9CYP2E1 | |
| SCHEMBL6211022 | 0.72 | AR (0.43) | IDO1AR | |
| SCHEMBL29891719 | 0.72 | AR (0.43) | IDO1AR | |
| SCHEMBL3432674 | 0.72 | AR (0.43) | IDO1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907408-B | Heterocyclic compound, intermediate thereof, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4289846-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4174069-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
| CN-113880843-B | Heterocyclic compound and application thereof | 武汉朗来科技发展有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-114907408-A | Heterocyclic compound, intermediate thereof, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2022-08-16 | — | — | CN | disclosed |
| WO-2022001767-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | 武汉朗来科技发展有限公司 | 2022-01-06 | — | — | WO | disclosed |
| CN-113880843-A | Heterocyclic compound and application thereof | 武汉朗来科技发展有限公司 | 2022-01-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TRPC5, TRPC1, GOT1 | IDO1 184/4885AR 3746/4885CYP2C19 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.